文献速递肾小球疾病

Atacicept治疗IgA肾病的2b期随机双盲安慰剂对照临床试验

A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
PubMed 文献 · Kidney Int · 2024-03-27

ORIGIN研究纳入116例经活检证实的IgA肾病患者,随机接受atacicept 150、75或25 mg或安慰剂每周一次治疗至36周。主要终点第24周时,atacicept 150 mg与75 mg联合组较安慰剂显著降低24小时尿蛋白肌酐比25%;第36周关键次要终点显著降低35%,且eGFR稳定。安全性特征与安慰剂相似。

要点

  • Atacicept 150/75 mg联合组第24周尿蛋白肌酐比较基线降低31%,安慰剂组降低8%,组间差异25%。
  • 第36周联合组尿蛋白肌酐比较基线降低34%,安慰剂组升高2%,组间差异35%。
  • 第36周atacicept组eGFR稳定而安慰剂组下降,组间几何均值差异11%(绝对差异约5.7 mL/min/1.73m2)。

核心结论

  • Atacicept在IgA肾病患者中显著降低蛋白尿并稳定eGFR,安全性特征与安慰剂相似,支持开展3期关键研究。

研究设计与样本

  • 随机、双盲、安慰剂对照2b期临床试验ORIGIN,纳入116例经活检证实的IgA肾病患者。
  • 参与者随机接受atacicept 150、75或25 mg或安慰剂每周一次,治疗至36周。
  • 主要终点为第24周24小时尿蛋白肌酐比较基线变化,关键次要终点为第36周相应变化,比较atacicept 150 mg与75 mg联合组 versus 安慰剂。

主要发现

  • 第24周主要终点达标:联合组尿蛋白肌酐比较基线降低31%,安慰剂组降低8%,组间显著降低25%。
  • 第36周关键次要终点达标:联合组尿蛋白肌酐比较基线降低34%,安慰剂组升高2%,组间显著降低35%。
  • 第36周atacicept组eGFR稳定而安慰剂组下降,组间几何均值差异11%,绝对差异约5.7 mL/min/1.73m2。
  • 终点半乳糖缺陷型IgA1水平较基线显著降低60% versus 安慰剂。
  • 安全性特征与安慰剂相似。

临床怎么用

  • Atacicept 150 mg或75 mg每周一次可显著降低IgA肾病患者蛋白尿并稳定肾功能,安全性可接受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atacicept is a first-in-class, dual anti-B-cell Activation Factor-A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in patients with IgAN, this randomized, double-blind, placebo-controlled phase 2b clinical trial ORIGIN enrolled 116 individuals with biopsy-proven IgA nephropathy. Participants were randomized to atacicept 150, 75, or 25 mg versus placebo once weekly for up to 36 weeks. Primary and key secondary endpoints were changes in urine protein creatinine ratio based on 24-hour urine collection at weeks 24 and 36, respectively, in the combined atacicept 150 mg and 75 mg group versus placebo. The primary endpoint was met at week 24 as the mean urine protein creatinine ratio was reduced from baseline by 31% in the combined atacicept group versus 8% with placebo, resulting in a significant 25% reduction with atacicept versus placebo. At week 36, the key secondary endpoint was met as the mean urine protein creatinine ratio reduced from baseline by 34% in the combined atacicept group versus a 2% increase with placebo, resulting in a significant 35% reduction with atacicept versus placebo. The reduction in proteinuria was accompanied by stabilization in endpoint eGFR with atacicept compared to a decline with placebo at week 36, resulting in significant between-group geometric mean difference of 11%, approximating an absolute difference of 5.7 mL/min/1.73m2. Endpoint galactose deficient IgA1 levels significantly decreased from baseline by 60% versus placebo. The safety profile of atacicept was like placebo. Thus, our results provide evidence to support a pivotal, phase 3 study of atacicept in IgA nephropathy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Lafayette R, Barbour S, Israni R, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024. PMID: 38552841. doi:10.1016/j.kint.2024.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。